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Candida auris is a novel and 
emerging fungal pathogen 
capable of causing invasive, 
and often fatal bloodstream 
and wound infections in 
immunocompromised patients. 
Several outbreaks have been 
reported in hospitals across the 
world, including the United 
States, and predominantly in 
New York. C. auris exhibits 
extensive multidrug resistance 
that has never been seen in 
any Candida species, and is 
often misdiagnosed for other 
Candida species, thus limiting 




Strains: 10 C. auris strains  
from the Centers for Disease 
Control, USA, were used in this 
study and maintained on YPD 
agar.
Minimum Inhibitory 
Concentration: MIC was 
performed per Clinical and 
Laboratory Standards Institute 
guidelines. Strains were 
suspended in RPMI-MOPS 
growth media, counted via 
hemocytometer, and transferred 
to a 96-well plate and subjected 
to Fluconazole (2-512 μg/ml) for 
48h at 37oC. 
Infection studies: C. auris was 
used to infect Galleria 
mellonella as described 
previously (Cotter et al., 2000). 
Strains were suspended in YPD 
broth and CFU was determined 
via hemocytometer. 105 CFU/ 
larvae or PBS control was 
injected into worm proleg, and 
were monitored for 16d. Dead 
or pupated worms were 
removed from the experiment. 
Macrophage killing assay was 
performed as previously 
described, Bouklas et. al. 2013.
Killing of C. auris strains was
determined in LPS and IFN-y
stimulated murine macrophage cell
line, J774.16 post 1h of phagocytosis
and 1h of killing. 40-60% killing was
observed on average, although
killing rates were highly variable
between strains.
Acknowledgments
• Determine the MIC of other 
antifungal drug classes, such 
as polyenes and 
echinocandins.
• Establish lethal dose for mice 
studies.
• Evaluate drug therapy on 
















• 70% of the C. auris strains 
tested demonstrate a high 
drug-resistance (>256 ug/mL) 
to azoles, specifically 
fluconazole, due to an as yet 
undetermined mechanism.
• C. auris strains demonstrate 
variable fitness as observed by 
their different growth rates with 
replication times ranging from 
30min to 90min.
• C. auris strains demonstrate 
variable virulence in an 
infection model, which may 
stem from their response to the 
hemocyte’s phagocytic ability.
• C. auris strains are killed 
variably by murine 
macrophages, and may 
therefore invoke different 
immune responses in a 
mammalian host.
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p < 0.0001 by Log Rank Test
A representative 96-well plate
demonstrating MIC of CAU-03 using
serial dilutions of fluconazole. The
first concentration exhibiting
inhibitory action is 128 μg/mL.
Growth curve of CAU-01, 02, and 03
plotted by Optical Density (600 nm)
versus time. All strains exhibited
exponential doubling time at
approximately 5h.
Comparative virulence of C. auris
strains in the Galleria host with a PBS 
control for comparison. Percentage of 
survival was calculated 16d post-
inoculation.
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